片仔癀药业品牌怎么样 申请店铺

我要投票 片仔癀药业在医疗保健行业中的票数:589 更新时间:2025-12-14
片仔癀药业是哪个国家的品牌?「片仔癀药业」是 漳州片仔癀药业股份有限公司 旗下著名品牌。该品牌发源于福建,由创始人刘建顺在1555期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力片仔癀药业品牌出海!将品牌入驻外推网,定制片仔癀药业品牌推广信息,可以显著提高片仔癀药业产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

片仔癀药业怎么样

漳州片仔癀药业股份有限公司,是漳州市制药厂改制创立的,是全国“重合同、守信用”企业、国家火炬高新技术企业、福建省百家重点工业企业、居我国中成药行业50强。公司连续多年入选福建省工业主要行业竞争力十强、工业300强、工业效益300强、利税300强。公司以生产名贵中成药——片仔癀而享誉海内外,注册的“片仔癀”商标于1999年元月被评为“中国驰名商标”,2006年入选商务部首批“中华老字号”、并入选中华老字号品牌价值百强榜20强,福建省出口名牌,片仔癀系列产品首批通过国家原产地标记认证,并被评为福建省名牌产品。2002年经国家人事部批准,设立博士后科研工作站。公司股票于2003年6月16日在上海证券交易所成功上市,2003年度列全国1200多家上市公司综合绩效排名第11位,2004年被评为福建省大、中型国有及国有控股企业效绩“十佳”。

公司的主导产品——片仔癀,两度荣获国家质量金质奖,并被列入国家中药一级保护品种,其以独特的消炎、解毒、镇痛、保肝等显著疗效及保护健康的功能而深受国内外患者的赞誉,被誉为“国宝神药”,并大量出口东南亚、日本、韩国、加拿大等国家和地区,年出口创汇超千万美元,居中国中成药单项出口创汇首位。2000年片仔癀作为内地第一个获得香港政府创新及科技基金无偿资助的中成药研究项目,由香港中文大学进行片仔癀保肝作用研究。

公司视产品质量为企业的生命,严格按国家GMP规范要求组织生产。公司始终重视新药的研发和老产品二次开发工作。近年来,相继研制开发投产了包括金糖宁胶囊、心舒宝片、清热止咳颗粒、复方片仔癀含片、增乳膏等在内的十几个新产品,使公司每年都有新产品面市,老产品二次开发--片仔癀胶囊增加适应症的临床研究被国家列入“863”计划。

目前公司有如下几个系列产品:

1.片仔癀系列:片仔癀、片仔癀胶囊、复方片仔癀软膏、复方片仔癀痔疮软膏、复方片仔癀含片;

2.感冒止咳系列:清热止咳颗粒、川贝清肺糖浆、藿香正气水(胶囊)、金牡感冒片、小柴胡颗粒、板蓝根颗粒、小儿止咳糖浆等;

3.丸剂系列:六味地黄丸、杞菊地黄丸、知柏地黄丸、香砂六君丸、逍遥丸;

4.保肝护肝类:茵胆平肝胶囊、护肝片;

5.妇女儿童类:增乳膏、逍遥丸、小儿止咳糖浆;

6.心血管类:心舒宝片、复方丹参片;

7.其它:少林正骨精、牛黄解毒片、蜂乳胶囊、金糖宁胶囊等等;

8.另外还有仅供国外销售产品:龙江牌特效片仔癀暗疮膏、复方片仔癀肝宝、片仔癀活络油、片仔癀白花蛇解痒片、片仔癀润喉片、片仔癀消炎胶囊、片仔癀润喉糖、片仔癀跌打精等。

Zhangzhou Pianzihuang Pharmaceutical Co., Ltd. was founded by Zhangzhou pharmaceutical factory. It is a national "contract and credit" enterprise, a national torch high-tech enterprise, a hundred key industrial enterprises in Fujian Province, and one of the top 50 Chinese patent medicine enterprises in China. For many years, the company has been selected as one of the top ten industrial competitiveness, top 300 industry, top 300 industrial efficiency and top 300 profit and tax. The company is famous at home and abroad for the production of famous Chinese patent medicine - pianzehuang. The registered "pianzehuang" trademark was rated as "China's famous trademark" in January 1999. In 2006, it was selected as the first batch of "China's time-honored brand" by the Ministry of Commerce, and was listed as the top 20 in the top 100 brand value list of China's time-honored brand. Fujian Province's export famous brand, pianzehuang series of products passed the national origin mark certification in the first batch, and was evaluated It is a famous brand product in Fujian Province. In 2002, with the approval of the Ministry of personnel of the people's Republic of China, a postdoctoral research station was established. The company's shares were successfully listed on the Shanghai Stock Exchange on June 16, 2003. In 2003, it ranked 11th in the comprehensive performance of more than 1200 listed companies in China. In 2004, it was rated as the "top ten" performance of large, medium-sized state-owned and state-owned holding enterprises in Fujian Province. The company's leading product, pianzehuang, has twice won the national quality gold medal and has been listed in the first level national protection of traditional Chinese medicine. It is highly praised by patients at home and abroad for its unique anti-inflammatory, detoxification, analgesic, liver protection and other remarkable curative effects and health protection functions. It is known as the "national treasure drug" and exported to Southeast Asia, Japan, South Korea, Canada and other countries and regions, The annual export earnings exceed ten million US dollars, ranking first in the single export earnings of Chinese patent medicine. In 2000, as the first Chinese patent medicine research project funded by the Hong Kong government innovation and science and technology fund, the Chinese University of Hong Kong carried out the research on the liver protection effect of Pianzihuang. The company regards product quality as the life of the enterprise and organizes production in strict accordance with the requirements of GMP. The company always attaches great importance to the research and development of new drugs and the secondary development of old products. In recent years, more than ten new products including Jintangning capsule, Xinshubao tablet, Qingre Zhike granules, compound Pianzihuang buccal tablet, Zengyao and so on have been developed and put into production successively, which makes the company have new products on the market every year. The second development of old products -- clinical research on the indication of increasing Pianzihuang capsule has been listed in the "863" plan by the state. At present, the company has the following series of products: 1. Pianzihuang series: Pianzihuang, Pianzihuang capsule, compound Pianzihuang ointment, compound Pianzihuang hemorrhoids ointment, compound Pianzihuang buccal tablet; 2. Cold and cough series: Qingre Zhike granules, Chuanbei Qingfei syrup, Huoxiang Zhengqi water (capsule), Jinmu cold tablet, Xiaochaihu granules, Banlangen Granules, Xiaoer Zhike syrup, etc.; 3. Pills Series: Liuwei Dihuang pill, Qiju Dihuang pill, Zhibai Dihuang pill, Xiangsha Liujun pill, Xiaoyao Pill; 4. Liver protection and liver protection: yindanpinggan capsule, Hugan tablet; 5. Women and children: Zengyao, Xiaoyao Pill, Xiaoer cough syrup; 6. Cardiovascular: Xinshubao tablet, Fufang Danshen tablet; 7. Others: Shaolin zhenggujing, Niuhuang Jiedu tablet, bee milk capsule, Jintangning capsule, etc.; 8 In addition, there are only foreign products for sale: Longjiang brand special effect pianzehuang acne cream, compound pianzehuang Ganbao, pianzehuang Huoluo oil, pianzehuang Baihua snake antipruritic tablet, pianzehuang Runhou tablet, pianzehuang Xiaoyan capsule, pianzehuang Runhou sugar, pianzehuang drop hit essence, etc.

本文链接: https://brand.waitui.com/5a0277eda.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

应对老年护理刚需,四部门发布《老年护理服务能力提升行动方案》

近日,国家卫生健康委、国家医保局、国家中医药局和国家疾控局四部门发布《老年护理服务能力提升行动方案》(以下简称《行动方案》)提出,到2027年,老年护理资源有效扩容,覆盖机构、社区、居家的老年护理服务体系逐步完善,从业人员服务能力不断提升,老年护理服务持续改善,服务连续性、可及性、规范性持续提高,老年人获得感不断增强。提升老年护理服务能力是深入贯彻实施积极应对人口老龄化国家战略的具体举措。截至2024年底,我国60岁及以上人口数达3.1亿,占总人口的22%,老年人特别是失能老年人对医疗护理服务呈现迫切的刚性需求。(央视新闻)

2小时前

消息人士称英伟达考虑提高H200芯片产量

消息人士称,英伟达考虑提高H200芯片产量。(新浪财经)

2小时前

中国造高端工业母机在沈阳下线交付

记者13日从通用技术沈阳机床获悉,由通用技术集团与东方电气集团联合研发的4台高端五轴联动数控机床12日在沈阳下线交付。这一合作在取得重大技术突破的同时,还打破了“研用脱节”的产业困境,开创了国产工业母机研制的新模式。长期以来,国产高端数控机床面临“研发投入大、周期长、验证难”的系统性瓶颈——企业闭门研发与市场实际需求脱节,产品因缺乏真实工况下的长期验证,陷入“用户不愿用、不敢用,技术难迭代、难成熟”的恶性循环,严重制约产业高质量发展。(中新网)

2小时前

金融时报:将坚持内需主导放在首位

金融时报评论员发布文章称,12月10日至11日,中央经济工作会议在京举行。会议聚焦“当前怎么看”和“明年怎么干”,为中国经济高质量发展把舵定向。站在“十四五”规划收官与“十五五”规划谋篇的历史交汇点,会议强调持续扩大内需、优化供给,将“坚持内需主导,建设强大国内市场”确定为明年经济工作重点任务之首。未来一个时期,我国国内市场主导国民经济循环的特征将更为明显。在内外部发展环境更趋严峻复杂的大背景下,只有坚持立足国内,全方位扩大内需、建设强大国内市场,增强发展主动性,才能够在国际风云变幻中,牢牢把握发展主动权。着眼明年经济社会发展目标任务,做强国内大循环,建设强大国内市场,以国内循环的稳定性对冲国际循环的不确定性,必须坚持内需的主导地位。坚持内需主导,全方位扩大国内需求,要大力提振居民消费。坚持内需主导,全方位扩大国内需求,要推动投资止跌回稳。将坚持内需主导放在首位,是党和国家对当前经济形势的深刻洞察。要全面贯彻明年经济工作的总体要求和政策取向,加快培育完整内需体系,形成消费和投资相互促进的良性循环,将超大规模市场的潜力转化为现实增长动力。

2小时前

脑虎科技:公司“三全”脑机接口产品成功完成首例临床试验

在今日举行的2025天桥脑科学研究院脑机接口与人工智能论坛中,脑虎科技方面表示,公司自主研发的国内首款、国际第二款内置电池的全植入、全无线、全功能(“三全”)脑机接口产品,在复旦大学附属华山医院毛颖、陈亮教授团队的主持下,成功完成首例临床试验。(财联社)

2小时前

本页详细列出关于片仔癀药业的品牌信息,含品牌所属公司介绍,片仔癀药业所处行业的品牌地位及优势。
咨询